drugset / Trial / NCT00797108

A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization

NCT00797108

Phase 2 Completed 35 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test if intravenous sulopenem and an oral drug, PF-03709270 are safe and effective in patients that are hospitalized with community acquired pneumonia.

Timeline

Start
2009-01
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ceftriaxone Other / unclassified 2 g Intravenous
Subject Sulopenem Small molecule 600 mg Intravenous
Comparator amoxicillin/clavulanate Unknown 400 mg Oral
Subject sulopenem etzadroxil Small molecule 1000 mg Oral

Indications